Interest costs add to Swissray loss

Article

A big jump in sales for the year didn't help digital x-ray developer Swissray International, which posted a large net loss for its 1998 fiscal year (end-June). The New York City-based company indicated that it sustained a net loss of $22.5 million for

A big jump in sales for the year didn't help digital x-ray developer Swissray International, which posted a large net loss for its 1998 fiscal year (end-June). The New York City-based company indicated that it sustained a net loss of $22.5 million for the year, compared with a $13.7 million net loss in 1997. Swissray's 1998 sales were $22.9 million, compared with $13.2 million the previous year.

Swissray attributed its net loss to an increase in interest expenses resulting from convertible debentures issued for financing reasons. The firm also incurred significant expenses for its ddR Multi-System product and spent R&D cash for Tahoma TMSSM, a new healthcare asset management software offering.

The company's 74% increase in net sales was in part due to Swissray's purchase of Empower and Service Support Group. Empower was later sold to E.M. Parker. Swissray also enjoyed rising sales under its Philips OEM agreement, and the company sold four ddR Multi-Systems during fiscal year 1998.

The financial results released in December were part of the company's 10-K filing, the submission of which had been delayed by the company. In October, the NASDAQ stock exchange cited the company's failure to file its year-end results on time as part of the reason it was delisted. Swissray executives claimed that the firm's delay was due to the hiring of a new accountant firm, PricewaterhouseCoopers, and the time required to prepare the report (SCAN 11/11/98).

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.